The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for women at 2 years by 
The Magpie Trial: a randomised trial comparing
magnesium sulphate with placebo for
pre-eclampsia. Outcome for women at 2 years
Magpie Trial Follow-Up Study Collaborative Group
Correspondence: Dr L Duley, Magpie Trial Ofﬁce, Nufﬁeld Department of Medicine, Level 5, John Radcliffe Hospital,
Headington, Oxford OX3 9DU, UK. Email lelia.duley@ndm.ox.ac.uk
Accepted 4 October 2006. Published OnlineEarly 12 December 2006.
Objective The aim of this study was to assess long-term effects for
women following the use of magnesium sulphate for pre-eclampsia.
Design Assessment at 2–3 years after delivery for women recruited
to the Magpie Trial (recruitment in 1998–2001, ISRCTN
86938761), which compared magnesium sulphate with placebo for
pre-eclampsia.
Setting Follow up after discharge from hospital at 125 centres in
19 countries across ﬁve continents.
Population A total of 7927 women were randomised at the follow-
up centres. Of these women, 2544 were not included for logistic
reasons and 601 excluded (109 at a centre where <20% of women
were contacted, 466 discharged without a surviving child and 26
opted out). Therefore, 4782 women were selected for follow-up,
of whom 3375 (71%) were traced.
Methods Questionnaire assessment was administered largely by
post or in a dedicated clinic. Interview assessment of selected
women was performed.
Main outcome measures Death or serious morbidity potentially
related to pre-eclampsia at follow up, other morbidity and use of
health service resources.
Results Median time from delivery to follow up was 26 months
(interquartile range 19–36). Fifty-eight of 1650 (3.5%) women
allocated magnesium sulphate died or had serious morbidity
potentially related to pre-eclampsia compared with 72 of 1725 (4.2%)
women allocated placebo (relative risk 0.84, 95% CI 0.60–1.18).
Conclusions The reduction in the risk of eclampsia following
prophylaxis with magnesium sulphate was not associated with an
excess of death or disability for the women after 2 years.
Keywords Longterm follow-up, magnesium sulphate, pre-eclampsia,
randomised trial.
Please cite this paper as: Magpie Trial Follow-Up Study Collaborative Group. The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo
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Introduction
Pre-eclampsia complicates 2–8% of pregnancies.1 Although
outcome is often good, pre-eclampsia is a major cause of mater-
nal and perinatal morbidity and mortality.2–5 Whether pre-
eclampsia has longer term consequences for the health of both
the woman and her child is unclear, although hypertension
during pregnancy does seem to be associated with an increase
in cardiovascular mortality for the woman in her later life.6,7
The Magpie Trial,8 a large international study, is a rando-
mised comparison of magnesium sulphate with placebo for
women with pre-eclampisa. This trial showed that magne-
sium sulphate halves the relative risk (RR) of eclampsia, with-
out appearing to have substantive harmful effects on either
the mother or the baby in the short term.8,9 To date, there has
been no reliable assessment of whether8 magnesium sulphate
inﬂuences long-term outcome following pregnancy compli-
cated by pre-eclampsia.10,11 We therefore contacted women
recruited to the Magpie Trial when their children were 18
months or older. The main objective was to determine
whether magnesium sulphate affects the child’s chance of
surviving without neurosensory disability, and these data
are reported elsewhere.12 Secondary objectives, which are
reported in this article, were to determine the effects of
magnesium sulphate on longer term outcome for women to
Re-use of this article is permitted in accordance with the Creative Commons
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assess prognosis for this international cohort of women with
pre-eclampsia.
Methods
Between 1998 and 2001, 10 141 women were recruited to the
Magpie Trial at 175 hospitals in 33 countries.8 The women
were eligible for the trial if they had pre-eclampsia (blood
pressure ‡140/90 mmHg and 1+ proteinuria) during preg-
nancy, if in labour or up to 24 hours postpartum and if there
was uncertainty about whether to use magnesium sulphate.
They were randomly allocated to receive either magnesium
sulphate heptahydrate 50% solution or placebo, given as
a loading dose plus 24 hours maintenance therapy.11 Each
hospital chose whether the maintenance regimen would be
intravenous or intramuscular for the duration of the trial. For
the active arm, the loading dose was 4 g magnesium sulphate.
For the intravenous maintenance regimen, this was followed
by an intravenous infusion of 1 g magnesium sulphate per
hour. For the intramuscular maintenance regimen, the intra-
venous loading dose was combined with 10 g magnesium
sulphate intramuscularly, followed by 5 g magnesium sul-
phate intramuscularly every 4 hours.
Of the 10 141 women recruited to the trial, 10 110 were
included in the analysis of outcome at discharge from the
hospital.8 A further 2295 women were never eligible for follow
up: 98 for whom there were no data about delivery and out-
come at discharge from the hospital and 2197 at 50 centres,
predominantly in developing countries, where follow-up was
not thought possible. The main reasons for centres not partici-
pating in follow up were factors such as mobility of the local
population and inaccurate or no contact details provided at
discharge from the hospital or that there was no local coordi-
nator, often because the coordinator for the main trial had
left. The ﬂow chart of the women who ultimately participated
in this follow-up study is shown in Figure 1. Every individ-
ual involved in tracing and assessment remained blind to
the allocated treatment. The protocol for the follow-up
study, which includes examples of the questionnaires, is
7927 women
randomised at centres participating in
follow-up study
(125 centres in 19 countries)
2544 women not included in
follow-up study for logistic
reasons* 
4782 women
included in follow-up study
Allocated magnesium sulphate Allocated placebo
2374 women included 
6 died before discharge
2368 alive at discharge
2408 women included
10 died before discharge
2398 alive at discharge
683 women no response
1650 women analysed
1382 randomised before delivery 
268 randomised after delivery
1725 women analysed
1427 randomised before delivery
298 randomised after delivery
601 women excluded
109 from centre where <20%
of women were contacted  
466 discharged without a
surviving child 
26 who opted out
724 women no response
* At some centres, women were included in follow-up only if they were born within a prespecified time frame,
such as the last 1 or 2 years of recruitment (32 centres) or if they lived in a predefined geographic area.
1
Figure 1. Consort ﬂow for women included in the follow-up.
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collaborators.14
Ethics approval and consent
All the hospitals secured local research ethics committee
approval before starting recruitment to the main trial. Women
were informed that they might be contacted for follow up
prior to giving consent for recruitment. Therefore, some
centres did not require the follow-up study be resubmitted
to an ethics committee. Others required a new submission or
considered the follow-up protocol an amendment to the orig-
inal trial protocol. After discussion within the collaborative
group, it was agreed that permission to contact women dis-
charged from the hospital without a surviving child would
not be requested. This was a pragmatic decision designed to
ensure that our primary objective of assessing outcome for the
children could be achieved. It was based on the widespread
perception that such permission would be refused and that
requesting it might either substantially delay ethics approval
or lead to rejection of the study.
How women were assessed
Women were asked to complete a brief questionnaire asking
about their health and wellbeing.13 Apart from asking about
high blood pressure and use of medicines for the same, all the
questions were open ended, with the women asked to record
in their own words their health problems and reasons for
attending the clinic and/or the hospital. Questionnaires were
available in English and Spanish. They were sent by post,
administered in clinic or during a home visit or completed
over the telephone. If the family could not be contacted, then
the information about whether the women and the children
were ‘alive and well’ was collected, whenever possible, from
neighbours, relatives or outpatient records. If the child was
invited for a paediatric assessment,12 this opportunity was
taken to measure the woman’s blood pressure and to ask
her about possible hypertension.
In the UK, an additional questionnaire was sent to the wom-
an’s GP about 18 months after delivery, and the date and cause
of the death were provided by the Ofﬁce for National Statistics.
Data coding and review
Information collected as free text was coded to reﬂect the
underlying condition or group of conditions. Two obstetri-
cians (Jack Moodley and Edgardo Abalos) reviewed the data
for women who died and a third (Lelia Duley) reviewed the
data and coding for women reporting serious morbidity. Data
coding and review were blind to treatment allocation.
Outcome measures
The main outcome for women in the follow-up study was
prespeciﬁed as a composite measure of death or serious mor-
bidity potentially related to pre-eclampsia.13 This included
women who died either before or after discharge from the
hospital and those who survived but had one or more of renal
problems, stroke and severe hypertension at follow-up.
Hypertension and other health problems reported by the
women were secondary outcomes as were the reported use of
health service resources and use of prescribed drugs.
Sample size
Power of the study was estimated based on outcome for the
children.12,13 Nevertheless, we estimated that 2800–3350
women would be eligible for follow-up and that approxi-
mately 20% would not be contacted. After adjusting for this
expected loss to follow-up, it was anticipated that data would
be available for 2405–2850 women, 2095–2485 randomised
before delivery and 310–365 randomised after delivery.
Statistical analyses
Analyses were based on the groups to which the women had
been allocated at trial entry. Centres able to contact less than
20% of included families were excluded. For the main out-
come, statistical signiﬁcance was taken as the 5% level. Where
appropriate, results are presented as relative risk (RR) with
95% conﬁdence intervals. Women who died were excluded
from the analysis of other health problems and use of health
service resources.
Planned subgroup analyses13 were based on severity of the
woman’s pre-eclampsia at trial entry (severe, moderate or
mild), whether randomised before or after delivery and peri-
natal mortality (PNM) in the country (high, medium or
low).15 Severe pre-eclampsia was as deﬁned in the original
trial protocol.8 The deﬁnitions of moderate and mild pre-
eclampsia13 were agreed before the analysis of outcome at
discharge from the hospital. These two groups were previ-
ously reported as ‘nonsevere’ pre-eclampsia.8 PNM for
each country was grouped, as in our previous report,8 a high
PNM, more than 40 deaths per 1000 births; moderate,
20–40 deaths per 1000 births and low, less than 20 deaths
per 1000 births.15
Results
Overall, 125 centres in 19 countries in Africa, Asia, USA,
Australia and Europe participated in the follow-up. The coor-
dinating centre in Oxford traced families from the 67 UK
centres and provided support to local collaborators who
traced all other families. Data collection closed on 31 Decem-
ber 2003. Excluded were 466 women discharged from hospital
without a surviving child, 26 who opted out and 109 from
a centre that contacted less than 20% of families. Of the
women discharged without a surviving child, 36% had severe
pre-eclampsia at trial entry (58 of 169 versus 109 of 297), 52%
had moderate pre-eclampsia (84 versus 156) and 13% had
mild pre-eclampsia (27 versus 32). Included in the follow-up
Magpie Trial Follow Up Study Collaborative Group
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placebo, n = 2408) (Figure 1), 16 (0.3%) who died before
discharge from the hospital and 4766 who were alive at dis-
charge from the hospital.
Women included in the follow-up were similar to those in
the trial overall. The only substantive differences were that
a higher proportion of women included in follow-up came
from low or middle PNM countries (65% versus 44% in trial
overall); so more of them received the intravenous mainte-
nance regimen for magnesium sulphate (67% versus 46%).8
In addition, fewer women included in the follow-up were
recruited at or before 33 completed weeks than those in the
trial overall (19% versus 27%).
Completeness of data
Data for 3375 women (71% with a response) were available for
the analysis, of whom 2809 were randomised before delivery
(Figure 1). For 143 women in the UK, information was from
the GP only. In the UK, 98% of women were contacted. Out-
side the UK, 11 centres contacted all included women and 36
contacted more than half of the included women. Data were
available for 49% of women in high PNM countries (807 of
1651), 74% in middle PNM countries (1365 of 1857) and 95%
in low PNM countries (1203 of 1272) (Table 1).
Outcome for the women
Outcome at discharge from hospital was similar for women
included in the follow-up and for those with a response
(Table 1). Five percent of surviving women responded to the
questionnaire within 12 months of delivery, 32% responded
13–24 months after delivery, 39% responded 25–36 months
after delivery, 16% responded 37–48 months after delivery
and4%respondedmore than 48monthsafterdelivery. Timing
of response was similar in the two treatment groups. For 5% of
women in both groups, data were only available from the UK
GP. Twenty-two percent of women in both groups had had
another pregnancy since the Magpie birth. At the time they
completed the questionnaire, 85 women allocated magnesium
sulphate were pregnant, as were 95 of those allocated placebo.
There were 62 women (1.8%) whose child had died after dis-
charge from the hospital (31 in each group).
Fifty-eight of the 1650 (3.5%) women allocated magnesium
sulphate died or had serious morbidity potentially related to
pre-eclampsia compared with 72 of the 1725 (4.2%) women
Table 1. Characteristics at trial entry, exposure to magnesium sulphate and outcome at discharge from hospital for women included in
follow-up and those who responded
Women included in follow-up Women with response
MgSO4, n 5 2374 Placebo, n 5 2408 MgSO4, n 5 1650 Placebo, n 5 1725
Characteristics of the women
Singleton pregnancy 2282 (96) 2322 (96) 1589 (96) 1662 (94)
Pre-eclampsia
Severe 528 (22) 564 (23) 385 (23) 408 (24)
Moderate 1071 (45) 1050 (44) 699 (42) 733 (43)
Mild 775 (33) 794 (33) 566 (34) 584 (34)
Prior anticonvulsant 139 (6) 164 (7) 89 (5) 105 (6)
33 completed weeks* 370 (19) 369 (18) 239 (17) 238 (17)
Postpartum 384 (16) 412 (17) 268 (16) 298 (17)
Characteristics of the centre
Intravenous maintenance regimen 1607 (68) 1613 (67) 1250 (76) 1275 (74)
High PNM country 817 (34) 834 (35) 386 (23) 421 (24)
Middle PNM country 927 (39) 932 (39) 671 (41) 694 (40)
Low PNM country 630 (27) 642 (27) 593 (36) 610 (35)
After trial entry
No exposure to MgSO4 34 (2) 2330 (97) 29 (2) 1663 (96)
Outcome at discharge from the hospital
Severe morbidity in hospital** 92 (4) 105 (4) 62 (4) 72 (4)
Admission to high care 1227 (52) 1237 (51) 857 (52) 882 (51)
Caesarean section* 1091 (55) 1023 (51) 776 (56) 728 (51)
Data are n (%).
*Women randomised before delivery only: included women in MgSO4 group, n 5 1990 and in placebo group, n 5 1996; traced women in MgSO4
group, n 5 1382 and in placebo group, n 5 1427.
**Includes eclampsia.
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Almostone-quarter of thewomen reported having highblood
pressure since their Magpie pregnancy (Table 2). Of the
women who did not report chronic hypertension, 219 of
1604 (14%) allocated magnesium sulphate had taken one or
more antihypertensive drugs for at least 2 weeks since their
Magpie pregnancy as had 250 of 1664 (15%) women allocated
placebo, and 106 of 1604 (7%) allocated magnesium sulphate
were taking antihypertensive(s) at the time of assessment as
were 127 of 1664 (8%) women allocated placebo.
Relative Risk
Favours MgSO4 Favours Placebo
.5 1 1.5 2 2.5
Relative risk
(95% CI)
No. of events
MgSO4 Placebo
All Women 0.84 ( 0.60–1.18) 58/1650 72/1725
Country
Low PNM 0.82 ( 0.45–1.48) 18/386 24/421
Middle PNM 0.80 ( 0.45–1.41) 20/671 26/694
High PNM 0.94 ( 0.52–1.70) 20/593 22/610
Pre-eclampsia
Severe 0.92 ( 0.62–1.37) 41/385 47/408
Mild/Moderate 0.71 ( 0.38–1.30)1 7/1265 25/1317
Randomisation
Before delivery 0.77 ( 0.54–1.12) 48/1382 64/1427
After delivery 1.39 ( 0.56–3.47) 10/268 8/298
Test of
interaction
P = 0.2
P = 0.5
P = 0.9
Figure 2. Death or serious morbidity related to pre-eclampsia at follow-up: prespeciﬁed subgroups.
Table 2. Death, serious morbidity potentially related to pre-eclampsia and hypertension for all women with response
MgSO4, n 5 1650 Placebo, n 5 1725
Death 18 (1.1) 17 (1.0)
Died before discharge from the hospital 6 10
Died after discharge from the hospital 12 7
Serious morbidity potentially related to pre-eclampsia* 40 (2.4) 55 (3.2)
Stroke —3
Serious renal problems 5 8
Severe hypertension** 35 47
Died or had serious morbidity potentially related to pre-eclampsia 58 (3.5) 72 (4.2)
Hypertension
Chronic hypertension 46 (3) 61 (4)
Reported having high BP before Magpie pregnancy*** 57 (4) 62 (3)
Reported having high BP since Magpie pregnancy*** 325 (20) 369 (21)
Taken antihypertensive drug since Magpie pregnancy**** 253 (15) 297 (17)
2 drugs since Magpie pregnancy**** 64 88
Taking antihypertensive drug ‘now’ 136 (8) 167 (10)
2 drugs ‘now’ 28 37
Data are n (%).
BP, blood pressure.
*Some women had more than one health problem.
**Deﬁned as hypertension and 2 antihypertensive drugs reported on the questionnaire.
***Excludes women with chronic hypertension, those with hypertension only on oral contraceptives and those with hypertension only during
another pregnancy.
****Excludes any antihypertensive drug taken within the ﬁrst 6 weeks after birth.
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reported at least one health problem (Table 3). The only out-
come for which the difference between the groups achieved
statistical signiﬁcance was gynaecological problems, for which
the risk was higher in the magnesium group (RR 1.59, 95%
CI 1.17–2.16). One hundred and fifty-four women (4.6%)
reported having psychosis or depression, requiring treatment,
of these 147 (95%) were from countries with low PNM. In
total, 195 women (5.8%) reported one or more mental health
problems. At least one mental health problem was reported by
184 of 1200 (15.3%) surviving women recruited in low PNM
countries, by 8 of 1352 (0.6%) surviving women recruited in
middle PNM countries and by 3 of 788 (0.4%) surviving
women recruited in high PNM countries. There were no clear
differences between the groups in the consumption of health
services (Table 4). Health problems and use of health service
resources were similar for women randomised before and for
those randomised after delivery (data not shown).
Overall, two-thirds of the surviving women contacted
(2136 of 3340) were interviewed alongside their child‘s assess-
ment, 1513 were interviewed within a week of responding to
the questionnaire, 222 within 2–4 weeks, and 382 after 4
weeks. Women who were interviewed were more likely to
have reported that they had high blood pressure on the ques-
tionnaire (386 of 1046 [37%] versus 447 of 1072 [42%]) than
women with a response overall (Table 2). Blood pressure was
measured during the interview for 1781 women, of whom 8%
were taking antihypertensive drugs at the time of the inter-
view (66 of 865 versus 88 of 916). Seventeen percent of
women had either systolic blood pressure ‡140 mmHg or
diastolic blood pressure ‡90 mmHg (134 of 865 versus 178
of 916), of whom one-third were taking an antihypertensive
at the time of the interview (39 versus 56). The proportion of
women with raised blood pressure taking an antihypertensive
drug was similar across the three categories of country.
Discussion
The use of magnesium sulphate for women with pre-eclamp-
sia was associated with a 16% reduction in the risk of death or
Table 3. Other reported health problems for surviving women with response
MgSO4, n 5 1632 Placebo, n 5 1708
Gynaecological problems*, n (%) 99 (6) 65 (4)
Menstrual disorder 46 31
Ovarian cyst or polycystic ovaries 3 3
Other or not speciﬁed 63 40
Minor ailment only**, n (%) 266 (16) 268 (16)
Other health problems*, n (%) 343 (21) 333 (19)
Psychosis or depression requiring treatment*** 71 83
Asthma or other respiratory problem 40 32
Serious infection 22 31
Mental health problem not requiring treatment*** 30 27
Gall bladder disease 12 19
Urinary tract infection or calculi 10 19
Liver problem 14 18
Diabetes 15 16
Thyroid disease 24 14
Cohn’s disease, ulcerative colitis, irritable bowel syndrome 15 14
Trauma 61 4
Cardiac problem (includes CHD and RHD) 6 11
Cancer 89
Epilepsy 97
Thromboembolic disease 5 5
Minor ailment plus other morbidity 189 188
Other or not speciﬁed 15 7
At least one health problem****, n (%) 1015 (62) 1059 (62)
CHD, congential heart disease; RHD, rheumatic heart disease.
*Some women had more than one health problem.
**Minor ailments included complaints such as colds, coughs, ﬂu, back problems, anaemia, piles and breast pains.
***Treatment included drugs and/or other forms of therapy.
****One or more of hypertension, gynaecological problem, morbidity potentially related to pre-eclampsia, other health problem, minor ailment,
visit to a clinic (excludes family planning or postnatal care) or admission to hospital (excludes for another pregnancy).
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years later. The confidence intervals suggest that the true
effect could be anything from a 40% reduction to an 18%
increase. Despite having prespecified a composite outcome,
our study had insufficient power to show a clear difference.
To illustrate the sort of sample size needed, for the placebo
group event rate of 4.2%, 26 000 women would have been
required to show a 16% difference in death or serious mor-
bidity potentially related to pre-eclampsia (a0.05, power
80%). Nevertheless, it is reassuring that the point estimate
consistently favours women allocated magnesium sulphate
(Figure 2). These data also provide reassurance that the use
of magnesium sulphate to reduce the risk of eclampsia is not
associated with unexpected adverse events for women in the
medium term. This reassurance is in addition to the data we
have already presented, showing no clear difference in the risk
of death or neurosensory disability at the age of 18 months for
children randomised while in utero.12
Although 50 centres were unable to participate in the
follow-up, this could not have introduced bias into the
assessment of outcome, as randomisation had been stratiﬁed
by the centre. As discussed in our accompanying article,12for
the 125 centres that did participate in the follow-up, it is
implausible that there was substantive bias in the selection of
families, as this process was conducted blind to the treat-
ment allocation. Bias in the assessment of outcome is simi-
larly implausible as this was also conducted blind to the
treatment allocation.
Inevitably, it was centres in low PNM countries that were
most likely to participate in the follow-up and were most
successful at contacting the women. Nevertheless, one-
quarter of women with a response were from high PNM
countries.
Although pre-eclampsia appears to be associated with
cardiovascular morbidity and mortality in later life,6,7 it
remains unclear whether this association is causal. Neverthe-
less, interventions to improve outcome following pre-eclamp-
sia might also improve longer term outcome for the women.
In this follow-up study, although the numbers were small and
there was no clear difference between the two groups at the
Table 4. Use of health service resources and drugs other than antihypertensives for surviving women with response
MgSO4, n 5 1632 Placebo, n 5 1708
Use of health service resources since delivery, n (%)
Attended clinic 527 (32) 583 (34)
Hospital admission 158 (10) 168 (10)
Reason(s) for hospital admission*
Surgery 37 31
Hypertension 17 33
Infection/HIV 91 6
Gastrointestinal problem 16 15
Psychiatric problem 45
Renal problem 44
Cardiac problem 14
Gynaecological problem 17 3
Stroke —1
Thromboembolic disease 4 1
Minor ailments 18 23
Other** 19 21
Drugs other than antihypertensives taken for .2 weeks***, n (%) 269 (16) 233 (14)
Antidepressant/sedative 59 64
Analgesia/anti-inﬂammatory 37 34
Antibiotic/antifungal 22 25
Gastrointestinal treatment 18 17
Asthma treatment 14 13
Diabetes treatment 71 1
Thyroid treatment 16 9
Steroid 83
Drug name not known 26 21
Other 33 21
*Excludes admission related to another pregnancy.
**Includes investigation, sterilisation, cancer, diabetes, epilepsy, arthritis, trauma, thyroid, serious liver problems and ear/hearing problems.
***Excludes nutritional supplements and contraception.
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sulphate had a stroke (zero versus three, serious renal prob-
lems (ﬁve versus eight) or severe hypertension (35 versus 47).
The Magpie Trial recruited a cohort of women with
pre-eclampsia; 2–3 years later, one in a hundred of these
women had died and a further three in a hundred had serious
morbidity potentially related to pre-eclampsia. About one-
quarter of the women reported having persistent high blood
pressure after the pregnancy in which they were recruited to
the trial, and one in ten were taking at least one antihyper-
tensive drug at the time of assessment. Although our study
does not provide data for a comparable group of women
without pre-eclampsia, this morbidity and mortality does
seem higher than might be expected following uncomplicated
pregnancy. For example, comparing outcome in the placebo
group for women with severe pre-eclampsia at trial entry with
that for those who did not have severe pre-eclampsia, there
was a six-fold difference in death or serious morbidity poten-
tially related to pre-eclampsia: 12.2% (47 of 385) for women
with severe pre-eclampsia compared with 1.9% (25 of 1317)
for those without. We did not attempt to assess women who
left hospital without a surviving child. These women were
more likely to have had severe pre-eclampsia at trial entry
and so might be expected to have higher levels of morbidity
and mortality at follow up. Therefore, our data may still have
underestimated the true risk of death or serious morbidity
related to pre-eclampsia.
Only one-third of surviving women did not report any
health problems. Information reported here was provided
by the women in response to questions about what problems
had led them to consult a doctor, attend a clinic or be admit-
ted to hospital. Hence, our data may underestimate the true
morbidity as women may have had problems but, for a variety
of reasons, not attended the health services. This is particu-
larly likely to be the case for women in the high and middle
PNM countries. For example, reported mortality was highest
in high PNM countries (1.6% for high PNM countries, 1.0%
for middle PNM countries and 0.4% for low PNM countries),
while serious morbidity potentially related to pre-eclampsia
was reported to be highest in low PNM countries (1.9% for
high PNM countries, 2.4% for middle PNM countries and
4.8% for low PNM countries). Gynaecological problems
appeared to be more common among women allocated mag-
nesium sulphate. This was an unexpected ﬁnding, and the
most likely explanation is that this is due to chance.
Depression is common following childbirth. In developed
countries, the prevalence of postnatal depression is around
13%.16 Within developing countries, depression after child-
birth may be even more prevalent, with levels of 30% or above
reported. 17,18 These estimates are largely based on prospective
studies that used self-completed questionnaires such as the
Edinburgh Postnatal Depression Scale and the Beck Depres-
sion Inventory and/or interviews. In contrast, we asked
women to report in their own words problems they had
experienced. We therefore expected that some women with
postpartum depression or other mood disorders would not
report this, purely because their symptoms had not been rec-
ognised or given a medical label. The 6% of women who
reported having at least one mental health problem almost
certainly represent substantial underascertainment. In partic-
ular, the low level reported by women in middle and high
PNM countries, less than 1% compared with 15% in low
PNM countries, should not be taken as a measure of the true
psychiatric morbidity. Lack of awareness and stigma may well
have contributed to underreporting. In addition, women at
greatest risk of postnatal depression may have been more
likely to opt not to respond to our questionnaire,19 and one
group of women at high risk for depression, those discharged
without a surviving child, were excluded from our study.
Our study was unique in contacting and assessing outcome
for women and their children after pregnancy complicated by
pre-eclampsia. The wide range of countries in which women
were contacted also means that with the limitations outlined
above, our results are generalisable to women in low, middle
and high PNM countries.
Conclusions
The reduction in the risk of eclampsia following prophylaxis
with magnesium sulphate was not associated with an excess
of death or disability for the women after 2 years.
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